Biotech makes a splash in HK as Ascletis prices IPO

By John Loh
26 Jul 2018

Ascletis Pharma priced its Hong Kong IPO in the middle of expectations on Wednesday, raising HK$3.1bn ($400m) from the city’s inaugural biotechnology offering.

Left lead Morgan Stanley, together with sponsors and global co-ordinators China Merchants Securities and Goldman Sachs, sold 224.1m primary shares in Ascletis at HK$14 a share — the midpoint of a HK$12 to HK$16 marketing range.

The issuer ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial